Fiona Rutherford Bloomberg
- All
- News
-
J&J Vaccine Gets Additional Warning On Bleeding Side Effect
The fact sheet for Johnson & Johnson's Covid-19 vaccine has been revised by U.S. regulators to warn of the risk of a rare bleeding disorder.
-
Now, 2 Covid Pills For At-Home Treatment As Omicron Spreads
Merck & Co.'s Covid-19 pill was cleared by US regulators Thursday, giving high-risk patients a second at-home treatment just as the Omicron variant is causing cases to surge around the country.
-
Merck's Covid Pill Shows Lower Efficacy In Updated Data
Merck & Co said updated results showed its Covid-19 pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%, less than a previous estimate and well below a rival treatment from Pfizer Inc.
-
Mix-And-Match Vaccines Have Big Benefit, Shows New US Study
Mixing Covid vaccines produces as much or more antibodies as using the same shot as a booster, according to preliminary results of a widely awaited US government-sponsored trial.
-
J&J's Covid Shot Gets US Regulator Warning About Rare Immune Disorder
The fact sheet for Johnson & Johnson's Covid-19 vaccine was revised to warn of the risk of a rare immune-system disorder, adding new headwinds for a shot once expected to be a linchpin of the US immunization effort.
-
Higher Risk Of Neurological, Mental Health Diagnoses After Covid: Study
A third of Covid-19 survivors were diagnosed with a neurological or psychiatric condition in the six months after being infected, according to the first large-scale research to compare the risks to other illnesses, including influenza.
-
J&J Vaccine Gets Additional Warning On Bleeding Side Effect
The fact sheet for Johnson & Johnson's Covid-19 vaccine has been revised by U.S. regulators to warn of the risk of a rare bleeding disorder.
-
Now, 2 Covid Pills For At-Home Treatment As Omicron Spreads
Merck & Co.'s Covid-19 pill was cleared by US regulators Thursday, giving high-risk patients a second at-home treatment just as the Omicron variant is causing cases to surge around the country.
-
Merck's Covid Pill Shows Lower Efficacy In Updated Data
Merck & Co said updated results showed its Covid-19 pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%, less than a previous estimate and well below a rival treatment from Pfizer Inc.
-
Mix-And-Match Vaccines Have Big Benefit, Shows New US Study
Mixing Covid vaccines produces as much or more antibodies as using the same shot as a booster, according to preliminary results of a widely awaited US government-sponsored trial.
-
J&J's Covid Shot Gets US Regulator Warning About Rare Immune Disorder
The fact sheet for Johnson & Johnson's Covid-19 vaccine was revised to warn of the risk of a rare immune-system disorder, adding new headwinds for a shot once expected to be a linchpin of the US immunization effort.
-
Higher Risk Of Neurological, Mental Health Diagnoses After Covid: Study
A third of Covid-19 survivors were diagnosed with a neurological or psychiatric condition in the six months after being infected, according to the first large-scale research to compare the risks to other illnesses, including influenza.
